NIOX(R) Approved In China

Main Category: Respiratory / Asthma
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 07 Dec 2007 - 12:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Aerocrine AB (STO:AERO) announces that the company's NIOX product has been approved by SFDA, the Chinese registration authority. Aerocrine has also entered into a distribution agreement with Bioson Inc. that includes sales of both NIOX and NIOX MINO in China.

NIOX is the first device for managing airway inflammation by measuring exhaled NO, that is approved for clinical use and marketing in China. Aerocrine and Bioson Inc. entered into collaboration in 2004 for distributing NIOX on the Chinese market. This agreement has now been expanded to include NIOX MINO.

Today, about five percent of teenagers in China have asthma symptoms and the corresponding adult figure is two percent. Around 40 million Chinese have asthma and this figure is increasing rapidly due to worsened environmental conditions and improved possibilities for diagnosis. The Chinese market for asthma drugs is estimated to increase from SEK 1.2 billion in 2006 to SEK 2.3 billion in 2011. China represents a significant future prospect for Aerocrine.

Bioson is a well-established company with its head office in Beijing and branches in 32 provinces. Bioson currently sells medical products to over 70 percent of all hospitals in China. Bioson is known for its high-quality products, service and support. Bioson is one of nine Chinese medical-technical companies that are selected partners of the Chinese Medical Association.

Aerocrine discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 AM on December 7, 2007.

About Aerocrine

Aerocrine AB is a clinically based medical technology corporation dedicated to improved asthma management and care. Aerocrine was listed on the Stockholm Stock Exchange on 15 June, 2007. The company is marketing NIOX® Flex on a worldwide basis and is also marketing NIOX MINO®, representing a new generation of hand-held devices, in Europe. Both products are tailored for rapid, non-invasive control of the inflammatory status in the airways and may play a critical role for optimized asthma care and disease control. Aerocrine is located in Sweden with wholly owned subsidiaries in the US, UK and Germany.

http://www.aerocrine.com/